CMNDHealthcare · Biotechnology

CMND Stock Forecast: Clearmind Medicine, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026

$1.63

−3.55% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap

$2.5M

Ticker Nerd rank

8 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

+0.6%

−30.9%

YTD

−91.0%

−99.6%

From 52W high

−99.7%

From 52W low

+11.6%

$476

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

CMND stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Clearmind Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

8 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Quality

Growth

Revisions

Volatility

Momentum

Issuance

Value

Size (98): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own Clearmind Medicine, Inc. — and when they’d sell — is the membership.

Wall Street

CMND stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CMND, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CMND analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Clearmind Medicine, Inc. (CMND) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.2×
Price / sales: —
Price / book: 0.1×
EV / EBITDA: 1.4×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −114.6%
Return on assets: −51.4%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CMND vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
CMNDClearmind Medicine, Inc.	$2.5M	8
GRIGRI Bio, Inc.	$2.4M	21
DCOYDecoy Therapeutics, Inc.	$2.4M	18
ARTLArtelo Biosciences, Inc.	$2.7M	15
OGENOragenics, Inc.	$2.2M	19
AZTRAzitra, Inc.	$2.1M	29
MBRXMoleculin Biotech, Inc.	$2.1M	11

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CMND appears on the weeks it earns a place.

News

Latest CMND news & analysis

Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company

GlobeNewsWire · 3 Aug 2026neutral

Clearmind Medicine announced it has signed a non-binding Letter of Intent to acquire a 51% majority stake in a company specializing in EV wireless charging solutions for automated parking systems and autonomous mobile platforms.

Why it matters — This move represents a significant strategic shift for Clearmind, a clinical-stage biotech company, by pursuing a majority stake in an unrelated technology sector.

Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial

GlobeNewsWire · 30 July 2026positive

Clearmind Medicine announced positive safety results from Part A of its Phase I/II clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder. All 24 participants across four ascending-dose cohorts completed treatment as planned per-protocol, demonstrating consistent tolerability.

Why it matters — Positive safety and tolerability data from an early-stage FDA-regulated trial reduces clinical risk for CMND-100, a key pipeline asset for Clearmind.

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

GlobeNewsWire · 28 July 2026positive

Clearmind Medicine announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for Alcohol Use Disorder.

Why it matters — This marks a key clinical milestone for CMND-100, Clearmind's lead candidate for AUD, bringing the drug one step closer to potential regulatory approval.

FAQ

Frequently asked questions about CMND stock

How does Ticker Nerd's model rank CMND?

As at 1 Aug 2026, Clearmind Medicine, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the CMND stock forecast for 2030?

No analyst covering Clearmind Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CMND are extrapolating price history, which says nothing about the business.

How has CMND stock performed over the past year?

Clearmind Medicine, Inc. returned -99.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Clearmind Medicine, Inc. do?

What is the latest news on CMND?

The most recent item we track (GlobeNewsWire, 3 Aug 2026): "Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company". Clearmind Medicine announced it has signed a non-binding Letter of Intent to acquire a 51% majority stake in a company specializing in EV wireless charging solutions for automated parking systems and autonomous mobile platforms.

Company

About Clearmind Medicine, Inc.

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address underserved health issues. Its primary efforts center on treatments for alcohol use disorder, including the lead candidate CMND-100, which is in an FDA-approved Phase I/IIa clinical trial, and MEAI, a non-hallucinogenic neuroplastogen targeted at obesity, metabolic disorders, compulsive eating, binge drinking, eating disorders, anxiety, depression, and post-traumatic stress disorder. The company also explores intranasal formulations and collaborations to enhance drug delivery for addiction-related and central nervous system conditions. Clearmind Medicine Inc. maintains an extensive intellectual property portfolio comprising 15 patent families with granted and pending patents across multiple jurisdictions. Founded in 2017 and headquartered in Vancouver, Canada, it operates as a key player in the emerging field of psychedelic medicines for mental health and behavioral disorders.

Canada · https://www.clearmindmedicine.com